DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight Insmed’s BRINSUPRI (brensocatib) has ...

"Non-Cystic Fibrosis Bronchiectasis Market"Non-Cystic Fibrosis Bronchiectasis companies working in the market are Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., ...

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non ...

December 17, 2010 (Dubai, United Arab Emirates) — Aspergillus infects as many as 10% of patients with bronchiectasis. The fungus has a unique self-defense mechanism against phagocytes, allowing it to ...

The Key Non-Cystic Fibrosis Bronchiectasis Companies in the market include - Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc ...

Treatment with the investigational anti-inflammatory drug brensocatib (formerly INS1007) significantly delayed the time to exacerbation in patients with the rare lung disease non-cystic fibrosis ...

The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...